# Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

> **NCT05509400** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 813 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo
- **DRUG:** Rimegepant

## Key facts

- **NCT ID:** NCT05509400
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-06-10
- **Target enrollment:** 813 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509400, "Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05509400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*